Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | UGCG | Q16739 | 2/20 | 0.42 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729095 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL729096 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL729681 | 0.90 | F13A1 (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL729680 | 0.90 | F13A1 (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL2220843 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL1965149 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL1964531 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL1964533 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL2167109 | 0.86 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL730005 | 0.82 | F13A1 (0.43) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137184-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8138181-B2 | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029633-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | SMN1; SMN2 3711/4885NPC1 3848/4885RAB9A 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.